Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 Stocks Estimated To Be Up To 49.2% Below Their Intrinsic Value

In This Article:

In the current global market environment, characterized by cautious Federal Reserve commentary and looming political uncertainties, investors are navigating a landscape of mixed economic signals. Despite these challenges, opportunities may exist in identifying stocks that are trading below their intrinsic value, offering potential for long-term growth as market conditions stabilize. In such a climate, a good stock is often one that demonstrates strong fundamentals and resilience amidst broader market volatility.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Clear Secure (NYSE:YOU)

US$26.66

US$53.14

49.8%

Sudarshan Chemical Industries (BSE:506655)

₹1129.90

₹2252.82

49.8%

Hanza (OM:HANZA)

SEK76.20

SEK151.92

49.8%

HealthEquity (NasdaqGS:HQY)

US$94.95

US$189.22

49.8%

Aguas Andinas (SNSE:AGUAS-A)

CLP293.50

CLP584.13

49.8%

Ingenia Communities Group (ASX:INA)

A$4.62

A$9.19

49.7%

South Atlantic Bancshares (OTCPK:SABK)

US$15.02

US$29.98

49.9%

KebNi (OM:KEBNI B)

SEK1.09

SEK2.17

49.8%

RENK Group (DB:R3NK)

€18.342

€36.50

49.7%

iFLYTEKLTD (SZSE:002230)

CN¥51.75

CN¥103.29

49.9%

Click here to see the full list of 875 stocks from our Undervalued Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Revenio Group Oyj

Overview: Revenio Group Oyj specializes in ophthalmological devices and software solutions for diagnosing glaucoma, macular degeneration, and diabetic retinopathy across Finland, Europe, North America, and internationally with a market cap of €714.37 million.

Operations: The company generates revenue of €102.49 million from its Health Tech segment, focusing on ophthalmological devices and software solutions.

Estimated Discount To Fair Value: 29.4%

Revenio Group Oyj is trading at €26.86, significantly below its estimated fair value of €38.02, indicating potential undervaluation based on cash flows. Despite a slight dip in third-quarter net income to €4.2 million from the previous year, revenues are projected to grow at 12.2% annually, outpacing the Finnish market's growth rate of 2.6%. Additionally, earnings are expected to increase by 19% per year, surpassing local market expectations of 14.2%.

HLSE:REG1V Discounted Cash Flow as at Dec 2024
HLSE:REG1V Discounted Cash Flow as at Dec 2024

Surgical Science Sweden

Overview: Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training across Europe, the Americas, Asia, and internationally, with a market cap of SEK8.24 billion.